Re: Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy

Affiliations

¹ Department of Urology, Erasmus MC, Rotterdam, The Netherlands. Electronic address: t.zuiverloon@erasmusmc.nl.
² Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA.

Comment

Tahlita C M Zuiverloon et al. Eur Urol. 2019 Apr.

. 2019 Apr;75(4):694.

doi: 10.1016/j.eururo.2018.12.019. Epub 2019 Jan 17.

¹ Department of Urology, Erasmus MC, Rotterdam, The Netherlands. Electronic address: t.zuiverloon@erasmusmc.nl.
² Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA.

No abstract available

Comment on

Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
Pietzak EJ, Zabor EC, Bagrodia A, Armenia J, Hu W, Zehir A, Funt S, Audenet F, Barron D, Maamouri N, Li Q, Teo MY, Arcila ME, Berger MF, Schultz N, Dalbagni G, Herr HW, Bajorin DF, Rosenberg JE, Al-Ahmadie H, Bochner BH, Solit DB, Iyer G. Pietzak EJ, et al. Eur Urol. 2019 Feb;75(2):231-239. doi: 10.1016/j.eururo.2018.09.002. Epub 2018 Oct 2. Eur Urol. 2019. PMID: 30290956 Free PMC article.